Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PolyPid Ltd PYPD

Healthcare Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.


NDAQ:PYPD - Post by User

PolyPid Ltd
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Aug 01, 2024 11:45pm
57 Views
Post# 36159810

PolyPid Announces Private Placement for Up to $14 Million in

PolyPid Announces Private Placement for Up to $14 Million in
BREAKING NEWS: $PYPD PolyPid Announces Private Placement for Up to $14 Million in Gross ProceedsFunding Extends Company&#x2019;s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of&#xA0;D-PLEX 100 for the Prev...PYPD - PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities